Literature DB >> 28445101

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion Summary.

Katherine S Virgo1, R Bryan Rumble1, Eric A Singer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28445101     DOI： 10.1200/JOP.2017.022970

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.

Authors:  K Kobayashi; N Okuno; G Arai; H Nakatsu; A Maniwa; N Kamiya; T Satoh; H Kikukawa; Y Nasu; H Uemura; T Nakashima; K Mikami; M Iinuma; K Tanabe; J Furukawa; H Kobayashi
Journal:  Jpn J Clin Oncol       Date:  2021-04-01       Impact factor: 3.019

2.  Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era.

Authors:  Isaac E Kim; Thomas L Jang; Sinae Kim; David Y Lee; Daniel D Kim; Eric A Singer; Saum Ghodoussipour; Mark N Stein; Monish Aron; Marc A Dall'Era; Isaac Yi Kim
Journal:  Cancer Med       Date:  2021-10-29       Impact factor: 4.452

3.  Effects of miR-129-3p on biological functions of prostate cancer cells through targeted regulation of Smad3.

Authors:  Yunpeng Jia; Yu Gao; Jianguo Dou
Journal:  Oncol Lett       Date:  2019-12-13       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.